Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this study, the addition of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, to standard care reduced cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk.
Type 2 diabetes is a major risk factor for cardiovascular disease,
1
,
2
and the presence of both type 2 diabetes a...
Alternative Titles
Full title
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1737477775
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1737477775
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1504720
